title: Reduction of calprotectin and phosphate during testosterone therapy in aging men: a randomized controlled trial.
abstract: OBJECTIVE
  To investigate the effect of testosterone treatment on biomarkers calprotectin, fibroblast growth factor 23 (FGF23), soluble Klotho, phosphate, calcium, parathyroid hormone, creatinine and estimated glomerular filtration rate.
  
  
  METHODS
  Randomized, double-blinded, placebo-controlled study.
  
  
  METHODS
  Odense Androgen Study-the effect of Testim and training in hypogonadal men.
  
  
  METHODS
  Men aged 60-78 years old with a low normal concentration of free of bioavailable testosterone <7.3 nmol/L and waist circumference >94 cm recruited from 2008 to 2009 (N = 48) by advertisement.
  
  
  METHODS
  Participants were randomized to receive 5-10 g gel/50-100 mg testosterone (Testim®, Ipsen, France) or 5-10 g gel/placebo.
  
  
  RESULTS
  The plasma levels of calprotectin and phosphate were significantly reduced in the group receiving testosterone therapy (gel) compared to the placebo group (p < 0.05). Testosterone treatment did not have any significant effect on plasma levels of FGF23 or soluble Klotho. The reduction in phosphate levels was inversely associated with bioavailable testosterone.
  
  
  CONCLUSIONS
  Compared to the placebo group, 6 months of testosterone therapy (gel) reduced calprotectin and phosphate levels suggesting decreased inflammation and decreased cardiovascular risk.
authors.affiliation: Department of Clinical Chemistry, Holbæk Hospital, Smedelundsgade 60, 4300, Holbæk, Denmark. liseped@regionsjaelland.dk.
authors.forename: L
authors.initials: L
authors.lastname: Pedersen
authors.affiliation: Department of Endocrinology, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense, Denmark.
authors.forename: L L
authors.initials: LL
authors.lastname: Christensen
authors.affiliation: Department of Clinical Chemistry and Pharmacology, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense, Denmark.
authors.forename: S M
authors.initials: SM
authors.lastname: Pedersen
authors.affiliation: Department of Endocrinology, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense, Denmark.
authors.forename: M
authors.initials: M
authors.lastname: Andersen
mesh_terms: D000368:Aged; D000375:Aging / Q000187:drug effects / Q000502:physiology*; D000728:Androgens / Q000008:administration & dosage* / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D000089703:Fibroblast Growth Factor-23; D005500:Follow-Up Studies; D006801:Humans; D039841:Leukocyte L1 Antigen Complex / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000097:blood*; D011379:Prognosis; D012307:Risk Factors; D013739:Testosterone / Q000008:administration & dosage* / Q000097:blood
chemical_list: D000728:Androgens; C000717427:FGF23 protein, human; D039841:Leukocyte L1 Antigen Complex; D010710:Phosphates; D013739:Testosterone; D000089703:Fibroblast Growth Factor-23
keywords: Biomarkers; Calprotectin; FGF23; Klotho; Phosphate; Testosterone therapy